A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia
Our study demonstrates that both alirocumab and evolocumab are effective in significantly reducing LDL-C levels in individuals with dyslipidemia. The mandated switch from alirocumab to evolocumab did not result in significant changes in LDL-C or clinical outcomes, suggesting that these treatments can be used interchangeably. These findings support the clinical equivalence of the two PCSK9 inhibitors and may guide therapeutic decisions in lipid management.
Authors
- Espen Jimenez‐Solem (ORCID: https://orcid.org/0000-0002-3777-147X)
- Michael Asger Andersen (ORCID: https://orcid.org/0000-0001-9729-9974)
- Tonny Studsgaard Petersen (ORCID: https://orcid.org/0000-0002-9974-2738)
- Anne Helms Andreasen (ORCID: https://orcid.org/0000-0002-2350-9884)
- Lia E. Bang
Institutions
- Frederiksberg Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Center for Clinical Research and Prevention (DK)
Publication Details
- Journal
- Communications Medicine
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1038/s43856-024-00611-x
- Citations
- 3
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.72